External validation of the GRACE risk score and the risk-treatment paradox in patients with acute coronary syndrome.
Niels M R van der Sangen, Jaouad Azzahhafi, Dean R P P Chan Pin Yin...
https://pubmed.ncbi.nlm.nih.gov/35354660/Actively Recruiting
Led by J.M. ten Berg · Updated on 2019-01-30
99999
Participants Needed
4
Research Sites
N/A
Total Duration
This research focuses on patients with acute coronary syndrome ACS, a leading cause of death worldwide. It aims to create an ongoing registry to evaluate the long-term effects of diagnostics, treatments, and devices used for ACS in real-world clinical practice. The study addresses gaps left by traditional randomized controlled trials by capturing data from routine care and broader patient populations to improve cardiovascular care and quality of life. The study uses a nonrandomized observational design to collect detailed clinical and possibly genetic information from patients with ACS. This registry allows evaluation of various therapies, devices, and diagnostic tools used in daily practice. It also examines follow-up care pathways, risk score usage for medication duration, and adherence to treatment guidelines, aiming to enhance personalized medicine and secondary prevention. Participants provide information during routine clinical visits, with data collected prospectively and followed over time. Researchers monitor outcomes such as mortality, recurrent ischemic events, hospital admissions, and quality of life. The main measure is the number of participants tracked at three years. This long-term observation helps evaluate the effectiveness and safety of treatments in everyday clinical settings and supports ongoing improvements in ACS care.
CONDITIONS
Future Optimal Research and Care Evaluation
D
Dean R.P.P. Chan Pin Yin, MD
J
Jur M. Ten Berg, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
J.M. ten Berg
Lead Sponsor
Vereniging Hart-Beter
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants are observed over time to collect data on clinical outcomes, medication use, devices, diagnostic tools, and healthcare pathways in daily clinical practice for acute coronary syndrome.
Follow-up visits according to routine clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Niels M R van der Sangen, Jaouad Azzahhafi, Dean R P P Chan Pin Yin...
https://pubmed.ncbi.nlm.nih.gov/35354660/Wout W A van den Broek, Jaouad Azzahhafi, Qiu Ying F van de Pol...
https://pubmed.ncbi.nlm.nih.gov/41744086/Wout Willem Antoon van den Broek, Jaouad Azzahhafi, Dean R P P Chan Pin Yin...
https://pubmed.ncbi.nlm.nih.gov/39537191/Dean R P P Chan Pin Yin, Gert-Jan A Vos, Niels M R van der Sangen...
https://pubmed.ncbi.nlm.nih.gov/33007932/J.M. ten Berg
Lead Sponsor
Vereniging Hart-Beter
Collaborating Sponsor